Cardio Diagnostics Holdings, a trailblazer in artificial intelligence-powered precision cardiovascular medicine tests, has announced the acquisition of an Innovation Technology contract from Vizient, the nation’s largest provider-driven healthcare performance improvement company. This milestone solidifies Cardio Diagnostics’ position at the forefront of cutting-edge healthcare technology. Following the announcement the shares of Cardio Diagnostics Holdings experienced a significant surge.
At the time of this publication, Cardio Diagnostics Holdings Inc stock (CDIO) has witnessed a surge.
Cardio Diagnostics Holdings Inc
Current Price: $0.32
Change : +0.11
Change (%): (51.97%)
Volume: 86.6M
Source: Tomorrow Events Market Data
The AI-driven molecular heart disease tests introduced by Cardio Diagnostics Holdings are engineered to pinpoint objective epigenetic and genetic biomarkers in patients who are either suspected to be at risk or already diagnosed with coronary heart disease. This technological breakthrough promises to revolutionize the diagnosis and management of cardiovascular conditions.
Vizient commands an impressive customer base, serving over 60% of hospitals and a staggering 97% of academic medical centers across the United States. Through this strategic agreement, Vizient’s extensive network of healthcare providers gains privileged access to Cardio Diagnostics’ state-of-the-art tests at specially negotiated pricing, thereby expanding the availability of the next generation of cardiovascular disease diagnostics.
The contract, slated to take effect on November 1, has been bestowed upon Cardio Diagnostics Holdings based on a resounding endorsement from the council of esteemed hospital experts of Vizient. This prestigious accolade underlines the unique attributes of Cardio Diagnostics’ offerings and their potential to instigate positive transformation within the healthcare industry.
Central to Cardio Diagnostics’ innovative approach are the Epi+Gen CHD and PrecisionCHD tests, which leverage a proprietary AI algorithm to scrutinize objective epigenetic and genetic biomarkers extracted from a patient’s blood sample. This integration of artificial intelligence with DNA analysis stands as the cornerstone of their groundbreaking methodology. These highly sensitive tests proficiently identify individuals at risk of developing coronary heart disease or those who may already be afflicted, all through a straightforward blood test that can be administered remotely or within a healthcare provider’s facility.
Expressing her gratitude, Cardio Diagnostics CEO, Meesha Dogan, PhD., who also played a pivotal role in inventing the technology, stated, “We are honored to receive this contract from Vizient, which will expedite access to our innovative heart disease tests that harness the power of AI and a precision medicine approach.” Dr. Dogan went on to highlight the contract’s endorsement of their mission to redefine cardiovascular disease management through advanced diagnostics. She further expressed the team’s enthusiasm for advancing cardiovascular care accessibility nationwide through this groundbreaking agreement.
Vizient’s clientele encompasses a diverse array of healthcare entities, including academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers, collectively representing an annual purchasing volume exceeding $130 billion. Operating through its Innovative Technology Program, Vizient collaborates closely with customer-led councils and task forces to evaluate potentially groundbreaking products. In cases where a product is deemed truly innovative, Vizient may opt to award a contract outside the conventional competitive bid cycle.
